ROIV 241220 12.00C (ROIV241220C12000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ROIV241220C12000

Watchlist

0.35
-0.05-12.50%

15min DelayClose Dec 4 16:00 ET

0.35High0.35Low

Intraday

5D
Daily

News

European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Seeking AlphaDec 3 11:49 ET
Roivant Sciences Ends Namilumab Study Due to Inefficacy
TipRanksDec 3 07:47 ET
Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study
WSJDec 3 07:35 ET
Express News | Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study
ReutersDec 3 07:05 ET
Express News | Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit
ReutersDec 3 07:00 ET
Express News | Roivant Sciences Ltd - Kinevant to Discontinue Namilumab Development for Sarcoidosis
ReutersDec 3 07:00 ET

Comments

Jaguar8

Dec 3 06:07

NEWS

$Roivant Sciences (ROIV.US)$
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Movers and Shakers

Apr 2 07:16

Columns Today's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More

Morning Movers
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Moomoo AI

Jan 5 04:55

The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.

Have Roivant Sciences Insiders Been Selling Stock?